A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

NCT ID: NCT02508194

Last Updated: 2017-12-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 1900 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-29
• Study Completion Date: 2016-11-07

Brief Summary

This study will be the first assessment of the efficacy of MEDI7510 for the prevention of respiratory syncytial virus (RSV) disease. It will also provide estimates of vaccine efficacy and of endpoint incidence in the placebo arm. It will also assess the safety and immunogenicity of concurrent dosing of MEDI7510 and IIV to expand on the observations made in the Phase 1b study of MEDI7510. It will also expand the safety database of participants dosed with MEDI7510. The study will also assess the immune response to MEDI7510 in Season 1 and Season 2.

Detailed Description

A Phase 2b, double-blind, randomized, and controlled study to evaluate the efficacy of MEDI7510 in approximately 1,900 adult participants, globally, 60 years or older. Participants will be randomized in a 1:1 ratio to receive a single intramuscular dose of each of 2 study vaccines in contralateral arms: MEDI7510 + IIV or placebo + IIV in Season 1.

Participants who receive MEDI7510 in the Northern Hemisphere will be re-randomized and blinded in Season 2 to receive either MEDI7510 + IIV or placebo + IIV in a 1:1 ratio. Clinical efficacy will not be assessed in Season 2; however the safety of revaccination will be assessed in Season 2.

Conditions

Respiratory Syncytial Virus

Keywords

RSV; Older adults; MEDI7510; Vaccine; Efficacy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Placebo + Inactivated Influenza Vaccine (IIV)

Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.

Group Type: ACTIVE_COMPARATOR

IIV

Intervention Type: BIOLOGICAL

Marketed Inactivated Influenza Vaccine

Placebo

Intervention Type: OTHER

Sterile Saline

MEDI7510 + IIV

Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.

Group Type: EXPERIMENTAL

MEDI7510

Intervention Type: BIOLOGICAL

RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant

IIV

Intervention Type: BIOLOGICAL

Marketed Inactivated Influenza Vaccine

Interventions

MEDI7510

RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant

Intervention Type: BIOLOGICAL

IIV

Marketed Inactivated Influenza Vaccine

Intervention Type: BIOLOGICAL

Placebo

Sterile Saline

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age ≥ 60 years at the time of screening.
• Medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the subject appears likely to be able to remain in follow-up through the end of protocol-specified follow-up.
• (Season 2): Subject received MEDI7510 and IIV in the Northern Hemisphere in Season 1.

Exclusion Criteria

• History of allergy to any component of the vaccine.
• Receipt of seasonal influenza vaccine within 6 months prior to Season 1 dosing.
• History of allergy to or intolerance of IIV.
• Pregnancy or potential to become pregnant during the study. Females who (1) have had a menstrual period within the 12 months prior to study enrollment or (2) are undergoing any fertility treatment or who plan to undergo fertility treatments during the study period are excluded.
• History of Guillain-Barré syndrome.
• Previous vaccination against RSV.
• History of allergy to eggs in adulthood.
• History of or current autoimmune disorder, with the exception of stable, treated hypothyroidism caused by autoimmune thyroiditis, which is acceptable.
• Immunosuppression caused by disease, including human immunodeficiency virus infection (assessed by history), or medications. Any receipt of oral or intravenous glucocorticoid therapy within 30 days prior to enrollment or planned dosing within the follow-up period would disqualify. Topical, intranasal, inhaled, or intra-articular corticosteroids do not disqualify. Expected need for immunosuppressive medications during the follow-up period would disqualify.
• History of cancer within preceding 5 years other than treated non-melanoma skin cancer, locally-treated cervical cancer or in situ carcinoma of the breast.
• Receipt of any non-study vaccine within 28 days prior to study dosing or expected receipt of non-study vaccine prior to the Day 29 visit in Season 1.
• Receipt of any investigational product (IP) in the 90 days prior to randomization or expected receipt of IP during the period of study follow-up.
• Receipt of immunoglobulins or blood products within 4 months of study dosing (120 days) or expected receipt of immunoglobulins or blood products during the period of study follow-up.
• Current bleeding or clotting disorder including use of anticoagulants other than drugs with anti-platelet activity (such as nonsteroidal anti-inflammatory drugs, clopidogrel, ticagrelor or aspirin).
• History of alcohol or drug abuse or psychiatric disorder that, in the opinion of the investigator, would affect the subject's safety or compliance with study.
• (Season 2): Related Grade 3 or 4 adverse event (AE) including Grade 3 or 4 local reaction to either MEDI7510 or IIV, any adverse event of special interest (AESI) for an adjuvanted vaccine, or any related serious adverse event (SAE).

• Minimum Eligible Age: 60 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

MedImmune LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Sacramento, California, United States

Research Site

San Francisco, California, United States

Research Site

Aurora, Colorado, United States

Research Site

Littleton, Colorado, United States

Research Site

Lady Lake, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Orlando, Florida, United States

Research Site

Savannah, Georgia, United States

Research Site

Champaign, Illinois, United States

Research Site

Chicago, Illinois, United States

Research Site

Council Bluffs, Iowa, United States

Research Site

Augusta, Kansas, United States

Research Site

Wichita, Kansas, United States

Research Site

Edina, Minnesota, United States

Research Site

Cincinnati, Missouri, United States

Research Site

Kansas City, Missouri, United States

Research Site

Bellevue, Nebraska, United States

Research Site

Norfolk, Nebraska, United States

Research Site

Omaha, Nebraska, United States

Research Site

Rochester, New York, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Hickory, North Carolina, United States

Research Site

Raleigh, North Carolina, United States

Research Site

Rocky Mount, North Carolina, United States

Research Site

Winston-Salem, North Carolina, United States

Research Site

Akron, Ohio, United States

Research Site

Dakota Dunes, South Dakota, United States

Research Site

Knoxville, Tennessee, United States

Research Site

Nashville, Tennessee, United States

Research Site

Murray, Utah, United States

Research Site

Brampton, Ontario, Canada

Research Site

London, Ontario, Canada

Research Site

Newmarket, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Québec, , Canada

Research Site

Santiago, , Chile

Research Site

Santiago, , Chile

Research Site

Santiago, , Chile

Research Site

Santiago, , Chile

Research Site

Temuco, , Chile

Research Site

Paide, , Estonia

Research Site

Tallinn, , Estonia

Research Site

Tallinn, , Estonia

Research Site

Tallinn, , Estonia

Research Site

Daugavpils, , Latvia

Research Site

Jelgava, , Latvia

Research Site

Kuldīga, , Latvia

Research Site

Kaunas, , Lithuania

Research Site

Kaunas, , Lithuania

Research Site

Kaunas, , Lithuania

Research Site

Vilnius, , Lithuania

Research Site

Vilnius, , Lithuania

Research Site

Bellville, , South Africa

Research Site

Bloemfontein, , South Africa

Research Site

Cape Town, , South Africa

Research Site

Johannesburg, , South Africa

Research Site

Johannesburg, , South Africa

Research Site

Krugersdorp, , South Africa

Research Site

Pretoria, , South Africa

Research Site

Somerset West, , South Africa

Countries

United States; Canada; Chile; Estonia; Latvia; Lithuania; South Africa

References

Chang LA, Phung E, Crank MC, Morabito KM, Villafana T, Dubovsky F, Falloon J, Esser MT, Lin BC, Chen GL, Graham BS, Ruckwardt TJ. A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine. Sci Transl Med. 2022 Dec 21;14(676):eade0424. doi: 10.1126/scitranslmed.ade0424. Epub 2022 Dec 21.

Reference Type: DERIVED

PMID: 36542692 (View on PubMed)

Falloon J, Yu J, Esser MT, Villafana T, Yu L, Dubovsky F, Takas T, Levin MJ, Falsey AR. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. J Infect Dis. 2017 Dec 12;216(11):1362-1370. doi: 10.1093/infdis/jix503.

Reference Type: DERIVED

PMID: 29029260 (View on PubMed)

Other Identifiers

D4420C00005

Identifier Type: -

Identifier Source: org_study_id